Short Interest in HeartSciences Inc. (NASDAQ:HSCS) Decreases By 37.2%

HeartSciences Inc. (NASDAQ:HSCS) was the target of a large decline in short interest in July. As of July 15th, there was short interest totaling 77,601 shares, a decline of 37.2% from the June 30th total of 123,640 shares. Currently, 2.6% of the company’s stock are sold short. Based on an average trading volume of 58,703 shares, the days-to-cover ratio is currently 1.3 days.

Institutional Trading of HeartSciences

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC purchased a new position in HeartSciences Inc. (NASDAQ:HSCS) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned approximately 0.51% of HeartSciences as of its most recent filing with the Securities & Exchange Commission. 17.24% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.00.

HeartSciences Stock Down 3.7%

Shares of HSCS traded down $0.08 during mid-day trading on Thursday, reaching $2.08. 69,158 shares of the stock traded hands, compared to its average volume of 1,003,643. The firm has a market cap of $8.11 million, a price-to-earnings ratio of -0.53 and a beta of 1.78. The stock has a fifty day simple moving average of $2.30 and a 200 day simple moving average of $2.48. HeartSciences has a 12-month low of $1.63 and a 12-month high of $3.93.

HeartSciences (NASDAQ:HSCS) last announced its earnings results on Thursday, July 23rd. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.22). On average, equities research analysts expect that HeartSciences will post -3.02 earnings per share for the current fiscal year.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.